Abstract 4709: Broad activity for the combination of BET and MEK inhibitors across solid and hematologic cancers
Anastasia Wyce(GlaxoSmithKline (United States)), Olena Barbash(GlaxoSmithKline (United States)), Charles F. McHugh(GlaxoSmithKline (United States)), Daniel Felitsky(Target (United States)), Sakina Khaku(GlaxoSmithKline (United States)), Ramona Plant(Enzo Life Sciences (United States)), Melissa Stern(Merck & Co., Inc., Rahway, NJ, USA (United States)), Melissa C. Musso(GlaxoSmithKline (United States)), Lijoy K. Mathew(GlaxoSmithKline (India)), Jeanne J. Matteo(GlaxoSmithKline (United States)), Yan Degenhardt(Cancer Research Institute), Kathryn Keenan(GlaxoSmithKline (United States)), Christopher Carpenter(Beaumont Hospital, Royal Oak), Peter J. Tummino(Intarcia Therapeutics (United States)), Susan Korenchuk(GlaxoSmithKline (United Kingdom)), Xiping Zhang(Fudan University), Victoria Rodríguez Ortiz(GlaxoSmithKline (United States))
Cited by 0
Related Papers
Genome sequencing in microfabricated high-density picolitre reactors
|Nature|2005|7.7k
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550